Remedium Bio is a gene therapy company developing treatments that target large unmet clinical needs, using novel combinations of proven technologies. By targeting indications optimally suited for gene therapy, involving local delivery using well characterized vectors and transgenes, our approach streamlines development to enable rapid value creation. The company’s lead candidate is the only single injection treatment potentially capable of reversing cartilage loss in Osteoarthritis ($38B market, 9% CAGR) – based on the clinically proven mechanism of FGF18. Our team of seasoned industry executives and clinical KOLs with 50+ years combined experience in rheumatology. In vitro and in vivo results from an ongoing collaboration with Tufts University are confirming the advantages and significant potential of Remedium’s proprietary solution.